AGP Picks
View all

AGP Executive Report

Last update: 8 hours ago

Vaccine Research Dispute: Guinea-Bissau’s health minister says the country has not authorized a Danish-led hepatitis B study in newborns, despite approval from a Danish university ethics committee. The US-funded proposal would enroll 14,000 babies, with half receiving the birth dose at six weeks instead; officials say research involving children must meet national and international ethical rules. Regional Tech: Guinea-Bissau-based experts joined Orange Cameroun’s cloud workshop in Douala, where more than 30 specialists discussed the future of the telecom group’s cloud platform.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
an hour ago

Stand Up for Science publishes Guinea-Bissau vaccine trial investigation

AGP

fallback image
Oct. 13, 2026

Stand Up for Science pushes Congress to halt CDC vaccine study in Guinea-Bissau

AGP

fallback image
Oct. 8, 2026

Stand Up for Science blasts CDC plan to revive Guinea-Bissau vaccine study

AGP

fallback image
Sep. 7, 2026

ROX opens Abu Dhabi AI manufacturing center, starts local vehicle production

AGP


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate Press Release Service
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Press Release Service
Guinea-Bissau Has Not Approved Hep B Vaccine Trial in Newborns

Guinea-Bissau Has Not Approved Hep B Vaccine Trial in Newborns

Danish University Approves CDC-Funded Trial That Would Delay Hepatitis B Shots for Half of 14,000 Newborns in Guinea-Bissau

Danish University Approves CDC-Funded Trial That Would Delay Hepatitis B Shots for Half of 14,000 Newborns in Guinea-Bissau


fallback image
an hour ago

As CDC Renews Controversial Guinea-Bissau Vaccine Trial, Stand Up for Science Makes Its Field Investigation Public

EIN Presswire

fallback image
Oct. 13, 2026

Stand Up for Science Launches Petition to Halt CDC Vaccine Study in West Africa

EIN Presswire

fallback image
Oct. 8, 2026

Stand Up for Science Condemns CDC’s Attempts to Restart Controversial Vaccine Study in Guinea-Bissau

EIN Presswire

fallback image
Feb. 22, 2026

Guinea-Bissau Stops Trump-Backed Hepatitis B Vaccine Study

MENAFN

fallback image
Feb. 22, 2026

Guinea-Bissau Stops US-Funded Hepatitis B Vaccine Trial

MENAFN

fallback image
Sep. 29, 2026

Itafos Enhances Financial Flexibility and Liquidity with an Amendment and Extension of Its Existing Credit Facilities

GlobeNewswire, Inc.

More press releases

Video Stories

YouTube video thumbnail:  Guinea-Bissau Junta Head Fires Officer Close to Former President Embaló
Play
Guinea-Bissau Junta Head Fires Officer Close to Former President Embaló
YouTube video thumbnail:  Mali Hosts More Than 322,000 Refugees and Asylum Seekers
Play
Mali Hosts More Than 322,000 Refugees and Asylum Seekers
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail:  Ghana Repatriates 120 Nigerians Rescued From Alleged Cybercrime Networks
Play
Ghana Repatriates 120 Nigerians Rescued From Alleged Cybercrime Networks
YouTube video thumbnail: Kenya Reports Second Ebola Case
Play
Kenya Reports Second Ebola Case

Video Title

Sign up for:

Guinea Bissau Tech Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Guinea Bissau Tech Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.